SMOKE FREE SWEDEN: DANSKE RESTRIKTIONER PÅ NIKOTINPOSER VIL FÅ 150.000 TIL AT VENDE TILBAGE TIL RYGNING
6.10.2024 17:00:00 CEST | Business Wire | Pressemeddelelse
Et foreslået forbud mod ni ud af ti nikotinposer i Danmark vil være et massivt tilbageskridt i kampen mod tobak og vil tvinge titusindvis af tidligere rygere tilbage til dødelige cigaretter, advarer førende internationale eksperter i dag.
Reguleringer på sundhedsområdet, som vil blive fremlagt for Folketinget fredag den 11. oktober, vil begrænse nikotinniveauet i en nikotinpose til 9 mg – langt under internationale standarder og kun en brøkdel af nikotinniveauet i cigaretter.
Dr. Delon Human, en global ekspert i skadereduktion og leder af ”Smoke Free Sweden”, siger: "Nikotinposer er bevist at være et langt sikrere alternativ til cigaretter og hjælper millioner af rygere med at stoppe over hele verden.”
"Forslaget, som Folketinget skal behandle, vil forbyde 90 % af de poser, der aktuelt bruges i Danmark, hvilket efterlader rygerne med valget mellem de få tilbageværende poser eller cigaretter, der indeholder 85 % mere nikotin.
"Det er ikke svært at forudsige, hvilket valg de vil ende med at træffe. Rygere, der overvejer at stoppe, vil blive nægtet et levedygtigt og sikrere alternativ, mens størstedelen af de 153.000 nuværende brugere af nikotinposer vil blive presset tilbage til cigaretter.
"At gøre den farligste måde at indtage nikotin på til den mest attraktive er simpelthen ulogisk og et massivt tilbageskridt i den fortsatte kamp mod tobakkens dødelige konsekvenser."
Danmarks naboland Sverige har vist, at en progressiv tilgang til skadesreducerende røgfrie nikotinprodukter er den bedste vej til at udrydde rygning og de sundhedskonsekvenser, som følger med.
Sverige har oplevet et ekstraordinært fald i antallet af rygere på 55 % over det seneste årti og er på nippet til officielt at blive erklæret røgfrit efter WHO’s målsætning. Sammenlignet med resten af EU har Sverige nu 44 % færre tobaksrelaterede dødsfald og en 41 % lavere kræftrate.
Sveriges succes tilskrives den udbredte brug af orale nikotinprodukter med forskellige nikotinstyrker og smagsvarianter samt regeringens politik med at lægge højere afgifter på cigaretter end på røgfrie nikotinprodukter.
Det danske forslag har til hensigt at forbyde de lange cigaretter, som i øjeblikket bruges af en tredjedel af rygerne, samtidig med at nikotinindholdet i poser begrænses.
"Forbuddet mod 30 % af cigaretterne på markedet burde være en stor mulighed for at opmuntre rygere til at skifte til sikrere alternativer som nikotinposer," siger Dr. Human. "I stedet forsøger forslagene at gøre poser ineffektive og mindre tiltalende end cigaretter.
"Som i Sverige bør den danske regering anerkende den vigtige rolle, disse skadesreducerede nikotinprodukter spiller i at hjælpe rygere med at overgå fra røgtobak og gøre sikrere alternativer tilgængelige, acceptable og til at betale."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20241006970721/da/
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum